We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

GlaxoSmithKline Extends GeneGo License and Adds New Products

Read time: Less than a minute

GeneGo, Inc. announced that GlaxoSmithKline has extended their licensing agreement with GeneGo and have added additional capability. This will provide GlaxoSmithKline researchers with global access to MetaCore, MapEditor and MetaBase.

MetaCore is GeneGo’s flagship platform for functional analysis of biological OMICs data featuring a comprehensive collection of pathway maps and network models for cellular processes and common diseases.

MetaCore is used for target identification, validation, biomarker discovery and knowledge mining. GlaxoSmithKline will also use the platform as a repository of all types of experimental data as well as resulting analyses.

All of this information can be shared with individuals or groups. MetaBase is direct access to the manually curated database of pathways, networks, ontologies, medicinal chemistry and diseases covering human, mouse and rat. MapEditor is a powerful research tool for creating intereractive custom maps which amalgamate MetaBase knowledge content with proprietary information and data.

“We have a good working relationship with GlaxoSmithKline developing new products such as our pay as you go 1-2-3 Workflow,” said Julie Bryant, GeneGo’s VP of Business development. “We will continue to work closely developing new functionality, tools and content for GlaxoSmithKline.”

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.